Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

Non-GAAP EPS Increased 22 Percent

CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, and strong progress across the company.

First-Quarter Highlights

-- Total revenue for the quarter grew 25 percent to $1.1 billion from

$883.2 million in same period a year ago. This increase was driven by

growth across all product lines, led by strong growth in sales of

treatments for lysosomal storage disorders and renal disease.

Genzyme's top line now includes sales of Aldurazyme(R) (laronidase),

which previously were recorded as joint venture revenue.

-- GAAP net income in the first quarter was $145.3 million, or $0.52 per

diluted share, compared with $158.2 million, or $0.57 per diluted

share. GAAP net income in this year's first quarter reflects an after-

tax charge of $56.5 million for the premium related to Genzyme's

strategic investment in Isis Pharmaceuticals Inc.

-- Non-GAAP net income increased 24 percent to $260.9 million, compared

with $210.7 million in the first quarter a year earlier. Non-GAAP

earnings increased 22 percent to $0.95 per diluted share from $0.78 per

diluted share in the first quarter last year.

-- Non-GAAP operating expenses decreased as a percentage of revenue,

reflecting global operating leverage.

-- Genzyme continued to generate significant cash from operations and to

reinvest in the future of the company. In the first quar
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... 21, 2014 Pursuit Solutions ( ... technology and services for Life Sciences sales and ... Use of New Commercial Sales Models” by Peter ... , The article examines some innovative models used ... being tested in the pharmaceutical market. Robinson grades ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/21/2014)... of last week RENU 28, the world's first and only ... purchase in Australia and New Zealand, and the response has ... if you think about the definition of aging, it's really ... your body. If you think about the definition of anti-aging, ... RENU 28 does is it works with these tiny little ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2
... COLOGNE, Germany and BANGALORE, India , ... laboratory worldwide in Electronics City in,the Indian city of ... in independent safety and quality testing for solar modules has,invested ... which in particular will,offer services to India,s growing ...
... Aug. 4 Amplimmune, Inc. today announced that it has ... PD-1 targeting therapies that may be effective in the treatment of cancer ... well as other potential next generation fusion proteins that target PD-1.   ... Under the ...
... 3 K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today that ... ("BDO") as the Company,s independent registered accounting firm. , ... The Company and BDO will commence work immediately on ... will then follow with the review of its quarterly filings for fiscal year ...
Cached Biology Technology:New Test Centre in India: TUV Rheinland Continues Worldwide Investment Programme for Solar Industry 2New Test Centre in India: TUV Rheinland Continues Worldwide Investment Programme for Solar Industry 3GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration 2GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration 3K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 2K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 3K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 4K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 5K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 6K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 7K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 8
(Date:8/21/2014)... of American singles found that during sex with ... rates. On average, men experience orgasm 85.1 percent ... little difference. For women, however, orgasm occurrence is ... percent of the time during sex with a ... women,s sexual orientation, with lesbian women experiencing orgasm ...
(Date:8/21/2014)... fungus linked to dandruff, eczema and other itchy, flaky ... further global reachesincluding Hawaiian coral reefs and the extreme ... A review in the scientific journal PLOS Pathogens ... fungi of the genus Malassezia in light ... from around the world. , University of Hawai,i at ...
(Date:8/21/2014)... In a finding that has implications for life in ... in the solar system, LSU Associate Professor of Biological ... National Science Foundation, or NSF, this week published a ... lake that lies 800 meters (2600 feet) beneath the ... microbial ecosystems.", Given that more than 400 subglacial lakes ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4
... new technique for turning embryonic stem cells into insulin-producing ... in the quest to find new treatments for diabetes. ... at the University of Sheffield, were able to genetically ... important protein known as a transcription factor. Stem ...
... camps atop glaciers in some of the most remote regions ... Branch at NASA,s Goddard Space Flight Center in Greenbelt, Md., ... Striking images taken by NASA satellites offer further visual evidence ... at the ends of the Earth. On Thursday, April ...
... Davis shows how our very short-term "working memory," which allows ... retains a limited number of high-resolution images for a few ... Humans rarely move their eyes smoothly. As our eyes flit ... to cut down visual "noise," said Steven J. Luck, professor ...
Cached Biology News:Stem cell breakthrough offers diabetes hope 2NASA expert to address Earth's vanishing polar ice, April 10, at UD 2Working memory has limited 'slots' 2